📢 New Clinical Trial: Alliance A082302 is studying if immunotherapy after surgery prevents recurrence in early non-small cell lung cancer (#NSCLC). The trial aims to enroll 336 participants to move from passive observation to active prevention. More at https://bit.ly/43SStJU.
October 12, 2026 at 6:00 PM
📢 New Clinical Trial: Alliance A082302 is studying if immunotherapy after surgery prevents recurrence in early non-small cell lung cancer (#NSCLC). The trial aims to enroll 336 participants to move from passive observation to active prevention. More at https://bit.ly/43SStJU.
HUTCHMED and AstraZeneca file US NDA for savolitinib plus osimertinib in MET-driven EGFR-mutated NSCLC, supported by Phase III PFS and OS data.
HUTCHMED files US NDA for savolitinib plus osimertinib in NSCLC
AstraZeneca has submitted a US NDA for savolitinib plus osimertinib in MET-driven EGFR-mutated NSCLC, backed by Phase III PFS and OS data.
biotech.disruptsmedia.com
October 12, 2026 at 2:00 PM
HUTCHMED and AstraZeneca file US NDA for savolitinib plus osimertinib in MET-driven EGFR-mutated NSCLC, supported by Phase III PFS and OS data.
Can imaging predict outcomes in advanced #LungCancer?
This study combines CT-based #radiomics, peritumoral features and clinical biomarkers to improve progression-free survival prediction in patients receiving #chemoimmunotherapy.
#currentmedicalscience: doi.org/10.1007/s115...
#Biotechnology
This study combines CT-based #radiomics, peritumoral features and clinical biomarkers to improve progression-free survival prediction in patients receiving #chemoimmunotherapy.
#currentmedicalscience: doi.org/10.1007/s115...
#Biotechnology
October 12, 2026 at 1:03 PM
Can imaging predict outcomes in advanced #LungCancer?
This study combines CT-based #radiomics, peritumoral features and clinical biomarkers to improve progression-free survival prediction in patients receiving #chemoimmunotherapy.
#currentmedicalscience: doi.org/10.1007/s115...
#Biotechnology
This study combines CT-based #radiomics, peritumoral features and clinical biomarkers to improve progression-free survival prediction in patients receiving #chemoimmunotherapy.
#currentmedicalscience: doi.org/10.1007/s115...
#Biotechnology
タイトル：肺がんの早期介入に向けた、浸潤前病変における制御性T細胞の調節軸
実験対象：浸潤前肺病変を追跡中の患者と、発がん物質で肺腫瘍を誘発したマウス
・患者では、進行性の浸潤前病変に伴い、血中のエフェクター制御性T細胞が増加した。
・マウスではPI3Kδ阻害により制御性T細胞の集積が抑えられ、肺腫瘍の発生率と大きさが低下した。
実験対象：浸潤前肺病変を追跡中の患者と、発がん物質で肺腫瘍を誘発したマウス
・患者では、進行性の浸潤前病変に伴い、血中のエフェクター制御性T細胞が増加した。
・マウスではPI3Kδ阻害により制御性T細胞の集積が抑えられ、肺腫瘍の発生率と大きさが低下した。
A preinvasive regulatory T cell axis for lung cancer interception.
【Nature】Late-stage non-small cell lung cancer (NSCLC) is rarely curable 1 , underscoring a need to intervene earlier in the diseas
pubmed.ncbi.nlm.nih.gov
October 11, 2026 at 8:08 AM
タイトル：肺がんの早期介入に向けた、浸潤前病変における制御性T細胞の調節軸
実験対象：浸潤前肺病変を追跡中の患者と、発がん物質で肺腫瘍を誘発したマウス
・患者では、進行性の浸潤前病変に伴い、血中のエフェクター制御性T細胞が増加した。
・マウスではPI3Kδ阻害により制御性T細胞の集積が抑えられ、肺腫瘍の発生率と大きさが低下した。
実験対象：浸潤前肺病変を追跡中の患者と、発がん物質で肺腫瘍を誘発したマウス
・患者では、進行性の浸潤前病変に伴い、血中のエフェクター制御性T細胞が増加した。
・マウスではPI3Kδ阻害により制御性T細胞の集積が抑えられ、肺腫瘍の発生率と大きさが低下した。
Exciting stuff for patients - now can't wait to see what the combo with chemo shows a la Flaura2
www.nejm.org/doi/full/10....
www.nejm.org/doi/full/10....
First-Line Sunvozertinib in NSCLC with EGFR Exon 20 Insertion Mutations | NEJM
Sunvozertinib received accelerated approval for use in later lines of therapy for patients with advanced non–small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 inse...
www.nejm.org
October 10, 2026 at 11:55 AM
Exciting stuff for patients - now can't wait to see what the combo with chemo shows a la Flaura2
www.nejm.org/doi/full/10....
www.nejm.org/doi/full/10....
A noninvasive spatiotemporal heterogeneity biomarker based on 18F-FDG PET-CT reliably predicted treatment response and prognosis in unresectable LA-NSCLC, offering insights to support personalized clinical decision making and precision oncology.
Read the article: https://bit.ly/4y5Nq5p
Read the article: https://bit.ly/4y5Nq5p
October 9, 2026 at 4:00 PM
A noninvasive spatiotemporal heterogeneity biomarker based on 18F-FDG PET-CT reliably predicted treatment response and prognosis in unresectable LA-NSCLC, offering insights to support personalized clinical decision making and precision oncology.
Read the article: https://bit.ly/4y5Nq5p
Read the article: https://bit.ly/4y5Nq5p
If you guessed C, you’re right! 🙌 Upstaged NSCLC needs adjuvant chemo, then immunotherapy for PD-L1 1% or higher.
Subscribe to ASCO-SEP® today: bit.ly/4zrBqwc
ASCO members get 20% off; additional discounts available.
Subscribe to ASCO-SEP® today: bit.ly/4zrBqwc
ASCO members get 20% off; additional discounts available.
October 9, 2026 at 2:07 PM
If you guessed C, you’re right! 🙌 Upstaged NSCLC needs adjuvant chemo, then immunotherapy for PD-L1 1% or higher.
Subscribe to ASCO-SEP® today: bit.ly/4zrBqwc
ASCO members get 20% off; additional discounts available.
Subscribe to ASCO-SEP® today: bit.ly/4zrBqwc
ASCO members get 20% off; additional discounts available.
Lazertinib Plus Pemetrexed and Carboplatin in Patients With EGFR-Mutant Advanced Non-Small Cell #LungCancer after Progression on Lazertinib. www.ejcancer.com/article/S095...
Lazertinib Plus Pemetrexed and Carboplatin in Patients With EGFR-Mutant Advanced Non-Small Cell Lung Cancer after Progression on Lazertinib
Therapeutic strategies after progression on third-generation EGFR tyrosine kinase
inhibitors (EGFR-TKIs) remain suboptimal in EGFR-mutant non-small cell lung cancer
(NSCLC). We investigated whether co...
www.ejcancer.com
October 9, 2026 at 9:26 AM
Lazertinib Plus Pemetrexed and Carboplatin in Patients With EGFR-Mutant Advanced Non-Small Cell #LungCancer after Progression on Lazertinib. www.ejcancer.com/article/S095...
The authors included RRIDs in their in Science Advances paper! Thanks for making your methods matter! #RRID #reproducibility #methodsmatter
A genome-wide genetic screen reveals the P2Y2-integrin axis as a stabilizer of EGFR mutants in non–small cell lung cancer (NSCLC)
Read the full paper: A genome-wide genetic screen reveals the P2Y2-integrin axis as a stabilizer of EGFR mutants in non–small cell lung cancer (NSCLC)
doi.org
October 9, 2026 at 7:15 AM
The authors included RRIDs in their in Science Advances paper! Thanks for making your methods matter! #RRID #reproducibility #methodsmatter
RRIDs were included in this in Nature Genetics paper. RRIDs improve reproducibility in scientific research. #RRID #STMpublishing #OpenScience
Lineage identity governs oncogene dependence in mouse NSCLC models of KRAS inhibitor resistance - Nature Genetics
KRAS-mutant lung cancers frequently develop resistance to targeted inhibition. This study demonstrates that lineage plasticity shapes oncogene dependence during response and resistance to KRAS inhibition, establishing new models of histologic transformation.
doi.org
October 9, 2026 at 7:09 AM
RRIDs were included in this in Nature Genetics paper. RRIDs improve reproducibility in scientific research. #RRID #STMpublishing #OpenScience
Cullinan files for FDA review of zipalertinib plus chemo in first-line EGFR ex20ins NSCLC, backed by Phase 3 data. Rare mutation, defined patient population, clearer regulatory path than the earlier second-line indication.
Cullinan files NDA for zipalertinib in first-line EGFR ex20ins NSCLC
Cullinan Therapeutics has begun an FDA RTOR submission for zipalertinib plus chemotherapy in first-line EGFR exon 20 insertion NSCLC, backed by Phase 3 data.
biotech.disruptsmedia.com
October 9, 2026 at 5:36 AM
Cullinan files for FDA review of zipalertinib plus chemo in first-line EGFR ex20ins NSCLC, backed by Phase 3 data. Rare mutation, defined patient population, clearer regulatory path than the earlier second-line indication.
🫁 This review analyzes the current evidence supporting established predictive #biomarkers, including PD-L1 expression, in the treatment of #NSCLC while highlighting their major limitations.
🔗 https://bit.ly/4hDUq4s
🔗 https://bit.ly/4hDUq4s
October 8, 2026 at 10:13 PM
🫁 This review analyzes the current evidence supporting established predictive #biomarkers, including PD-L1 expression, in the treatment of #NSCLC while highlighting their major limitations.
🔗 https://bit.ly/4hDUq4s
🔗 https://bit.ly/4hDUq4s
The trial compared the EGFR inhibitor firmonertinib to chemotherapy in patients with EGFR exon 20-mutant NSCLC.
ArriVent’s Firmonertinib Fails in First-Line EGFR-Mutant NSCLC Trial
ArriVent’s Firmonertinib Fails in First-Line EGFR-Mutant NSCLC Trial
ebx.sh
October 7, 2026 at 11:31 PM
The trial compared the EGFR inhibitor firmonertinib to chemotherapy in patients with EGFR exon 20-mutant NSCLC.
🫁 The @fda.gov has granted breakthrough therapy designation to telisotuzumab adizutecan monotherapy for previously treated, c-Met–expressing, EGFR wild-type nonsquamous NSCLC. #lcsm #oncology
Full story ➡️: www.onclive.com/view/fda-gra...
Full story ➡️: www.onclive.com/view/fda-gra...
FDA Grants Breakthrough Therapy Designation to Temab-A in Previously Treated c-Met–Expressing Nonsquamous NSCLC | OncLive
The c-Met–directed ADC was designated for EGFR wild-type nonsquamous NSCLC after platinum chemotherapy and anti–PD-(L)1 therapy.
www.onclive.com
October 7, 2026 at 4:28 PM
🫁 The @fda.gov has granted breakthrough therapy designation to telisotuzumab adizutecan monotherapy for previously treated, c-Met–expressing, EGFR wild-type nonsquamous NSCLC. #lcsm #oncology
Full story ➡️: www.onclive.com/view/fda-gra...
Full story ➡️: www.onclive.com/view/fda-gra...
Are you up to date with the latest advancements in the management of HER2-positive NSCLC? Gain practical insights on biomarker testing, HER2-targeted therapies, and emerging treatment strategies with this free video podcast series: her2-mutations-nsclc.ime.springermedicine.com/experts-in-c...
October 7, 2026 at 2:27 PM
Are you up to date with the latest advancements in the management of HER2-positive NSCLC? Gain practical insights on biomarker testing, HER2-targeted therapies, and emerging treatment strategies with this free video podcast series: her2-mutations-nsclc.ime.springermedicine.com/experts-in-c...
(WO2026200927A1) discloses an EGFR×cMET bispecific ADC with site-specific glycan conjugation of topoisomerase-I payloads. ADC1 showed activity in NCI-H1975 CDX and 12 osimertinib-resistant NSCLC PDX models, addressing heterogeneous resistance.
October 7, 2026 at 1:41 PM
(WO2026200927A1) discloses an EGFR×cMET bispecific ADC with site-specific glycan conjugation of topoisomerase-I payloads. ADC1 showed activity in NCI-H1975 CDX and 12 osimertinib-resistant NSCLC PDX models, addressing heterogeneous resistance.
Acute Interstitial Nephritis, Acute Tubular Injury, and Drug-Induced Phospholipidosis Associated with Combined KRAS G12C and RAF/MEK Inhibition in Non-Small Cell Lung Cancer - Kidney International Case Reports www.kicasereports.org/article/S311...
Highlights from March issue
Highlights from March issue
Acute Interstitial Nephritis, Acute Tubular Injury, and Drug-Induced Phospholipidosis Associated with Combined KRAS G12C and RAF/MEK Inhibition in Non-Small Cell Lung Cancer
Targeted therapies directed against oncogenic KRAS mutations have significantly improved
outcomes in non-small cell lung cancer (NSCLC), yet the renal safety profile of combined
KRAS pathway inhibitio...
www.kicasereports.org
October 7, 2026 at 12:31 PM
Acute Interstitial Nephritis, Acute Tubular Injury, and Drug-Induced Phospholipidosis Associated with Combined KRAS G12C and RAF/MEK Inhibition in Non-Small Cell Lung Cancer - Kidney International Case Reports www.kicasereports.org/article/S311...
Highlights from March issue
Highlights from March issue
📄 #IBRX 10-Q — what changed
MD&A now says: "Forward-looking statements include, but are not limited to: • our ability to successfully commercialize ANKTIVA globally in current and future approved indications (including NMIBC and NSCLC), and to obtain incremental regulatory approvals for new i
MD&A now says: "Forward-looking statements include, but are not limited to: • our ability to successfully commercialize ANKTIVA globally in current and future approved indications (including NMIBC and NSCLC), and to obtain incremental regulatory approvals for new i
FormDelta — Insider Trading Alerts
What ImmunityBio, Inc. changed in their own words, quarter over quarter.
www.formdelta.com
October 6, 2026 at 10:12 PM
🫁 Firmonertinib did not significantly improve BICR-assessed PFS vs platinum/pemetrexed chemotherapy in first-line EGFR exon 20–mutant NSCLC in the FURVENT trial. #lcsm #oncology
Full story ➡️: www.onclive.com/view/firmone...
Full story ➡️: www.onclive.com/view/firmone...
Firmonertinib Fails to Meet PFS End Point in First-Line EGFR Exon 20 Insertion–Mutant NSCLC | OncLive
Firmonertinib did not significantly improve BICR-assessed PFS vs platinum/pemetrexed chemotherapy in first-line EGFR exon 20–mutant NSCLC in FURVENT trial.
www.onclive.com
October 6, 2026 at 8:14 PM
🫁 Firmonertinib did not significantly improve BICR-assessed PFS vs platinum/pemetrexed chemotherapy in first-line EGFR exon 20–mutant NSCLC in the FURVENT trial. #lcsm #oncology
Full story ➡️: www.onclive.com/view/firmone...
Full story ➡️: www.onclive.com/view/firmone...
#$AVBP exon 20 lung cancer study missed its main goal. Safety was consistent, and the company is reviewing next steps. notreload.xyz/xy/arrivent-...
ArriVent Firmonertinib Misses Phase 3 Lung Cancer Goal
FURVENT failed its primary PFS endpoint in first-line EGFR exon 20 NSCLC. Response rates were higher, and cash funds operations into 2028.
notreload.xyz
October 6, 2026 at 2:15 PM
#$AVBP exon 20 lung cancer study missed its main goal. Safety was consistent, and the company is reviewing next steps. notreload.xyz/xy/arrivent-...
The EA5221/ACHIEVE clinical study is testing two different treatment approaches for older adults with advanced non-small cell #LungCancer. Learn more: https://bit.ly/ea5221-achieve #NSCLC #LCSM
October 6, 2026 at 2:00 PM
The EA5221/ACHIEVE clinical study is testing two different treatment approaches for older adults with advanced non-small cell #LungCancer. Learn more: https://bit.ly/ea5221-achieve #NSCLC #LCSM
🫁 Lung cancer experts discuss strategies after immunotherapy in advanced squamous NSCLC. @narjustflorezmd.bsky.social @christianrolfo.bsky.social @cityofhope.bsky.social @osucccjames.bsky.social @danafarber.bsky.social @iaslc.bsky.social #WCLC26 #lcsm #oncology
www.onclive.com/view/next-ge...
www.onclive.com/view/next-ge...
Next-Generation CTLA-4 Targeting Frames Post-Immunotherapy Squamous NSCLC Management | OncLive
Lung cancer experts discuss emerging strategies after immunotherapy in advanced squamous NSCLC, including updated PRESERVE-003 data from WCLC 2026.
www.onclive.com
October 6, 2026 at 1:40 PM
🫁 Lung cancer experts discuss strategies after immunotherapy in advanced squamous NSCLC. @narjustflorezmd.bsky.social @christianrolfo.bsky.social @cityofhope.bsky.social @osucccjames.bsky.social @danafarber.bsky.social @iaslc.bsky.social #WCLC26 #lcsm #oncology
www.onclive.com/view/next-ge...
www.onclive.com/view/next-ge...
$AVBP: Phase 3 FURVENT trial missed primary endpoint in EGFR exon 20 NSCLC, but showed clinical activity in secondary metrics. Management reviewing next steps.
www.biopharmcatalyst.com/news/2026/bi...
www.biopharmcatalyst.com/news/2026/bi...
Pre-Market Updates 10/06/26
export-download.canva.com
October 6, 2026 at 12:45 PM
$AVBP: Phase 3 FURVENT trial missed primary endpoint in EGFR exon 20 NSCLC, but showed clinical activity in secondary metrics. Management reviewing next steps.
www.biopharmcatalyst.com/news/2026/bi...
www.biopharmcatalyst.com/news/2026/bi...
Malinconico et al. engineered T cells with both a CAR targeting CD176 (expressed in NSCLC and other tumors), and an inducible cassette encoding either IL-18 or IL-12 that would be expressed following CAR activation of NF-κB. @aacrjournals.bsky.social
bit.ly/4rFOStG
bit.ly/4rFOStG
October 6, 2026 at 11:30 AM
Malinconico et al. engineered T cells with both a CAR targeting CD176 (expressed in NSCLC and other tumors), and an inducible cassette encoding either IL-18 or IL-12 that would be expressed following CAR activation of NF-κB. @aacrjournals.bsky.social
bit.ly/4rFOStG
bit.ly/4rFOStG
October 2: two SITC posters confirmed for November 6 and 7, on NSCLC multi-omics and linoserpaturev in recurrent glioblastoma.
Candel Therapeutics (#$CADL) Stock Hub 2026: Can Manufacturing Validation Clear The Way For The Q4 Prostate BLA?
www.merlintrader.com/candel-thera...
Candel Therapeutics (#$CADL) Stock Hub 2026: Can Manufacturing Validation Clear The Way For The Q4 Prostate BLA?
www.merlintrader.com/candel-thera...
Candel Therapeutics ($CADL): Q4 Prostate BLA And SITC Data
Candel Therapeutics ($CADL): manufacturing validation ahead of the Q4 2026 prostate BLA, SITC posters on November 6-7, $201.6M of cash, runway into Q1 2028.
www.merlintrader.com
October 6, 2026 at 10:32 AM
October 2: two SITC posters confirmed for November 6 and 7, on NSCLC multi-omics and linoserpaturev in recurrent glioblastoma.
Candel Therapeutics (#$CADL) Stock Hub 2026: Can Manufacturing Validation Clear The Way For The Q4 Prostate BLA?
www.merlintrader.com/candel-thera...
Candel Therapeutics (#$CADL) Stock Hub 2026: Can Manufacturing Validation Clear The Way For The Q4 Prostate BLA?
www.merlintrader.com/candel-thera...